Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients

Next Previous
Trial Profile

A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Diabetic foot ulcer; Embolism and thrombosis; Peripheral arterial occlusive disorders
  • Focus Therapeutic Use
  • Acronyms FEENICS
  • Sponsors Pfizer

Most Recent Events

  • 28 Apr 2012 Planned patient number for extension trial is 215 as reported by European Clinical Trials Database record (EudraCT2008-001566-90).
  • 28 Apr 2012 Planned patient number for extension trial is 215 as reported by European Clinical Trials Database record (EudraCT2008-001566-90).
  • 24 Mar 2011 Actual end date (October 2010) of extension trial (NCT00765063) added as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top